TTI 1612

Drug Profile

TTI 1612

Alternative Names: Soluble HB-EGF like growth factor - Stem Cell Therapeutics; Soluble heparin-binding epidermal growth factor-like growth factor - Stem Cell Therapeutics; TTI-1612

Latest Information Update: 30 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Trillium Therapeutics
  • Class Anti-inflammatories; Cytoprotectives; Growth factors; Recombinant proteins; Urologics
  • Mechanism of Action Epidermal growth factor receptor agonists; Epithelial cell stimulants; Intracellular signalling peptide and protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute enterocolitis
  • New Molecular Entity No
  • Available For Licensing Yes - Interstitial cystitis

Highest Development Phases

  • No development reported Interstitial cystitis
  • Discontinued Acute enterocolitis

Most Recent Events

  • 02 Jun 2014 Stem Therapeutics changes its name to Trillium Therapeutics
  • 16 May 2013 TTI 1612 is still available for partnering as of 16 May 2013.
  • 16 May 2013 Trillium Therapeutics completes dosing in its phase I trial in Interstitial cystitis in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top